Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 2Unknown 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Arthritis, Rheumatoid 8Psoriasis 7Lymphoma, Follicular 4Leukemia 4Myelodysplastic Syndromes 3Asthma 3Vasculitis 2Respiratory Distress Syndrome 2Recurrence 2Pneumonia 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Inflammation 2Granulomatosis with Polyangiitis 2Bronchiolitis Obliterans 2Arthritis, Psoriatic 2Arthritis, Juvenile 2Wilms Tumor 1Uveitis 1Temporomandibular Joint Disorders 1Spondylitis, Ankylosing 1Spondylarthritis 1Pruritus 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plaque, Amyloid 1Pancreatic Neoplasms 1Neuroblastoma 1Neoplasms 1Metabolic Syndrome 1

Interventions

Etanercept 2canakinumab 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Arthritis, Juvenile × Etanercept × Clear all
NCT03780959 2019-08-02

Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)

Amgen

Phase 2/3 Completed
69 enrolled 11 charts

Arthritis, Juvenile

NCT00001862 2008-03-04

TNRF:Fc to Treat Eye Inflammation in Juvenile Rheumatoid Arthritis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
15 enrolled

Arthritis, Juvenile, Inflammation, Uveitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡